Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-26
2011-04-26
Rao, Manjunath N (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S412000, C530S414000
Reexamination Certificate
active
07932355
ABSTRACT:
La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.
REFERENCES:
patent: 5522991 (1996-06-01), Tuccelli et al.
patent: 6967239 (2005-11-01), Chtourou et al.
patent: 2003/0232969 (2003-12-01), Lengsfeld et al.
patent: 2009/0176709 (2009-07-01), Nieto et al.
patent: 0 860 444 (1998-08-01), None
patent: 1 270 595 (2003-01-01), None
patent: 1 331 266 (2003-07-01), None
patent: 1 348 445 (2003-10-01), None
patent: 1 443 961 (2004-08-01), None
patent: WO 96/00237 (1996-01-01), None
patent: WO-99/31138 (1999-06-01), None
Weinstein, “Immunoaffinity Purification of Factor VIII”, Annals Of Clinical and Laboratory Science, vol. 19, No. 2, pp. 84-91, Mar. 1, 1989.
Mentzer et al., “Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis”, Haemophilia, vol. 4, No. 3, pp. 25-32, 1998.
Furuya et al., “Implementation of a 20-nm por-size filter in the plasma-derived Factor VIII manufacturing process”, Vox Sanguinis, vol. 19, pp. 119-125, 2006.
Advanced Catalogue Search, ATCC No. CRL-1662, Product Description, [online] [retrieved on Sep. 22, 2009]. Retrieved from the Internet: <URL: mhtml:file://W:\Intellectual Property\APPLICATIONS\OPPOSITIONS\LFB\atcc—crl ...>.
Advanced Catalogue Search, ATCC No. CRL-1823, Product Description [online] [retrieved on Sep. 22, 2009]. Retrieved from the Internet: <URL: http://www.Igcstandards-atcc.org/LGCAdvancedCatalogueSearch/Product Description...>.
Alberts, et al., Molecular Biology of The Cell, 3rdEd., p. 1206, Ch. 23:The Immune System, Garland Publishing, 1994.
Armstrong-Fisher et al., “Evaluation of a panel of human monoclonal antibodies to D and Exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function,”Transfusion, Aug. 1999, pp. 1005-1012, vol. 39.
Blood Plasma, Wikipedia, [online] [retrieved on Sep. 22, 2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Blood—plasma>, 3 pages. Revision history of Blood plasma, Wikipedia, [online] [retrieved Sep. 22, 2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/w/index.php?title=Blood—plasma&limit=500&action=history>, 18 pages.
Boyd et al., “The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H,”Mole. Immunol., 1995, pp. 1311-1318, vol. 32, Nos. 17/18.
Brand, A., “Immunosuppression and Immunomodulation,”Immunological and Infectious Diseases of the Peripheral Nerves, Latov et al., editors, Cambridge University Press, Chapter 24, pp. 366-368, 1998.
Bredius et al., “Role of neutrophile FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes,”Immunology, 1994, pp. 624-630, vol. 83.
Cant et al., “Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines,”Cytotechnology, 1994, pp. 223-228, vol. 15.
Carroll et al., “Mouse X human heterohybridomas as fusion partners with human,”J. Immunol. Methods, 1986, pp. 61-72, vol. 89, Elsevier.
CD61, Wikipedia, [online] [retrieved on Sep. 22, 2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/CD61, 5 pages. Revision history of CD61, [online] [retrieved on Sep. 22, 2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/w/index.php?title=CD61&action=history, 1 page.
Chowdhury et al., “Tailor-made antibody therapeutics,”Methods, 2005, pp. 11-24, vol. 36, Elsevier.
Ducrot et al., “Use of the DAF Assay to Assess the Functional Properties of Polyclonal and Monoclonal Rh D Antibodies,”Vox Sang, 1996, pp. 30-36, vol. 71.
Galili et al., “A Unique Natural Human IgG Antibody with Anti-α-Galactosyl Specificity,”J. Exp. Med., Nov. 1984, pp. 1519-1531, vol. 160.
Goossens, et al., “Human monoclonal antibodies against blood group antigens. Preparation of a series of stable EBV immortalized B clones producing high levels of antibody of different isotypes and specificities,”J. Immunol. Methods, 1987, pp. 193-200, vol. 101, Elsevier.
Greenman et al., “Comparative efficiencies of bispecific F(ab'γ)2and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fcγ receptors,”Cancer Immunol. Immunother, 1992, pp. 361-369, vol. 34.
Hadley et al., “The functional activity of FcγRII and FcγRIII on subsets of human lymphocytes,”Immunology, 1992, pp. 446-451, vol. 76.
Hsu et al., “DifferentialN-Glycan Patterns of Secreted and Intracellular IgG Produced inTrichoplusia niCells,”J. Biol. Chem., Apr. 1997, pp. 9062-9070, vol. 272, No. 14.
Hughes-Jones et al., “Nucleotide sequences and three-dimensional modeling of the VHand VLdomains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system,”Biochem. J., 1990, pp. 135-140, vol. 268.
Ip et al., “Structural Characterization of theN-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G,”Archives of Biochemistry and Biophysics, Feb. 1991, pp. 387-399, vol. 208, No. 2.
Jefferis et al., “IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation,”Immunol. Reviews, 1998, pp. 59-76, vol. 163.
Keler et al., “Bispecific antibody-dependent Cellular Cytotoxicity of HER2
eu-overexpressing Tumor Cells by Fcγ Receptor Type I-expressing Effector Cells,”Cancer Research, Sep. 1997, pp. 4008-4014, vol. 57.
Kilmartin et al., “Rat Monoclonal Antitubulin antibodies Derived by Using a New Nonsecreting Rat Cell Line,”J. Cell Biol., Jun. 1982, pp. 576-582, vol. 93.
Klein et al., “Human recombinant anti-Rh(D) monoclonal antibodies: Improvement of biological properties by in vitro class-switch,”Human Antibodies, 1997, pp. 17-25, vol. 8, No. 1.
Kumpel et al., “Activity and Fcγ receptor utilization of IgG anti-D monoclonal antibodies in monocytes chemiluminescence assays and lymphocyte ADCC assays,” 4thWorkshop on Mabs against human red blood cells and related antigens, PARIS, Jul. 19-20, 2002, p. 1.
Kumpel et al., “Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed By-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity,”Hum. Antibod. Hybridomas, 1994, pp. 143-151, vol. 5. Nos. 3 and 4.
Kumpel et al., Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis,Eur. J. Immunol., 1989, pp. 2283-2288, vol. 19.
Kumpel et al., “Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunication in Rh D- volunteers,”Blood, 1995, pp. 1701-1709, vol. 86, American Society of Hematology.
Kumpel, B.M., “Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers,”Vox Sang., 2007, pp. 99-111, vol. 93.
Kumpel, B.M., “Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn,”Transfus. Clin. Biol., 1997, pp. 351-356, vol. 4.
Lifely et al., “Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions,”Glycobiology, 1995, pp. 813-822, vol. 5, No. 8.
Lund et al., “Control of IgG/Fc Glycosylat
Chtourou Abdessatar
Nogre Michel
Schmitthaeusler Roland
Foley & Lardner LLP
LFB SA
Rao Manjunath N
Tsay Marsha M
LandOfFree
Virally-safe factor VIII with a low content of higher multimers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virally-safe factor VIII with a low content of higher multimers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virally-safe factor VIII with a low content of higher multimers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643899